Effects of acetylsalicylic acid on serum paraoxonase activity, Ox-LDL, coenzyme Q10 and other oxidative stress markers in healthy volunteers

Clinical Biochemistry

Volumn 43, Issue 3, 2010, Pages 287-290

  Kurban, Sevil ^a   Mehmetoglu, Idris ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Acetylsalicylic acid; Arylesterase; Coenzyme Q10; Oxidative stress; Oxidized LDL; Paraoxonase

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; ECOPIRIN; OXIDIZED LOW DENSITY LIPOPROTEIN; UBIDECARENONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ASPIRIN; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS, LDL; MIDDLE AGED; OXIDATIVE STRESS; UBIQUINONE;

EID: 74249101514     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.10.054     Document Type: Article

References (37)

1. Hennekens C.H. Update on aspirin in the treatment and prevention of cardiovascular disease. Am. J. Manag. Care 8 (2002) 691-700
2. Awtry E.H., and Loscalzo J. Aspirin. Circulation 101 (2000) 1206-1218
3. Mehta J.L. Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. Clin. Cardiol. 21 (1998) 879-884
4. Dhalla N.S., Temsah R.M., and Netticadan T. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 18 (2000) 655-673
5. Verhoye E., Langlois M.R., Rietzchel E., et al. Asklepios Investigators. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk. Clin. Chem. Lab. Med. 47 (2009) 128-137
6. Cyrus T., Yao Y., Tung L.X., and Praticò D. Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis 184 (2006) 8-14
7. Mehta J.L., Chen J., Yu F., and Li D.Y. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc. Res. 64 (2004) 243-249
8. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
9. Wu R., Lamontagne D., and de Champlain J. Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 105 (2002) 387-392
10. Costanzo A., Moretti F., Burgio V.L., et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J. Cell. Physiol. 195 (2003) 402-410
11. Tauseef M., Shahid M., Sharma K.K., and Fahim M. Antioxidative action of aspirin on endothelial function in hypercholesterolaemic rats. Basic Clin. Pharmacol. Toxicol. 103 (2008) 314-321
12. Podhaisky H.P., Abate A., Polte T., Oberle S., and Schröder H. Aspirin protects endothelial cells from oxidative stress-possible synergism with vitamin E. FEBS Lett. 417 (1997) 349-351
13. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 37 (2004) 1304-1316
14. Mackness M.I., Mackness B., Durrington P.N., et al. Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9 (1998) 319-324
15. Camps J., Marsillach J., and Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 46 (2009) 83-106
16. Jaichander P., Selvarajan K., Garelnabi M., and Parthasarathy S. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J. Lipid. Res. 49 (2008) 2142-2148
17. 10: recent developments. Mol. Biotechnol. 37 (2007) 31-37
18. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983) 1126-1138
19. Haagen L., and Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur. J. Clin. Chem. Clin. Biochem. 30 (1992) 391-395
20. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin. Biochem. 37 (2004) 277-285
21. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem. 38 (2005) 1103-1111
22. Kowalczyk E., Kopff A., Błaszczyk J., Fijałkowski P., and Kopff M. The influence of selected nonsteroidal anti-inflammatory drugs on antioxidative enzymes activity. Pol. Arch. Med. Wewn. 115 (2006) 112-117
23. Ibáñez-Hernández M.G., Macías-Islas M.A., Zavalza-Gómez A.B., Pacheco-Moisés F.P., and Ortiz G.G. The effect of ibuprofen and acetylsalicylic acid on cognitive impairment, total antioxidant power and isoprostane serum. Gac. Med. Mex. 144 (2008) 497-502
24. Sobal G., Menzel J.E., and Sinzinger H. Influence of acetylsalicylic acid on oxidation of native and glycated low-density lipoprotein. Life. Sci. 66 (2000) 1987-1998
25. Steer K.A., Wallace T.M., Bolton C.H., and Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart 77 (1997) 333-337
26. Kukreja R.C., Kontas H.A., Hess M.L., and Ellis E.S. PGH synthase and lipoxygenase generates superoxide in the presence ofNADH or NADPH. Circ. Res. 59 (1986) 612-619
27. Grootveld M., and Halliwell B. Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Biochem. J. 237 (1986) 499-504
28. Parthasarathy S., Khoo J.C., Miller E., Bamett J., Witzum J.L., and Steinberg D. Low density lipoprotein rich in oleic acid is protected against oxidative modification; implications for dietary prevention of atherosclerosis. Proc. Nat. Acad. Sci. U. S. A. 87 (1990) 3894-3898
29. Ashidate K., and Kawamura M. Mimura, et al. Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma. Eur. J. Pharmacol. 513 (2005) 173-179
30. Amann R., and Peskar B.A. Anti-inflammatory effects of aspirin and sodium salicylate. Eur. J. Pharmacol. 447 (2002) 1-9
31. Hermann M., Kapiotis S., Hofbauer R., et al. Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals. FEBS Lett. 445 (1999) 212-214
32. Gelvan D., Moreno V., Gassmann W., Hegenauer J., and Saltman P. Metal-iondirected site-specificity of hydroxyl radical detection. Biochim. Biophys. Acta. 1116 (1992) 183-191
33. Blatter-Garin M.C., Kalix B., De Pree S., and James R.W. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 46 (2003) 593-594
34. Karabina S.A., Lehner A.N., Frank E., Parthasarathy S., and Santanam N. Oxidative inactivation of paraoxonase-implications in diabetes mellitus and atherosclerosis. Biochim. Biophys. Acta 1725 (2005) 213-221
35. Kopff M., Kopff A., and Kowalczyk E. The effect of nonsteroidal anti-inflammatory drugs on oxidative/antioxidative balance. Pol. Merkur. Lekarski. 23 (2007) 184-187
36. Turunen M., Appelkvist E.L., Sindelar P., and Dallner G. Blood concentration of coenzyme Q(10) increases in rats when esterified forms are administered. J. Nutr. 129 (1999) 2113-2118
37. Aberg F., Zhang Y., Teclebrhan H., Appelkvist E.L., and Dallner G. Increases in tissue levels of ubiquinone in association with peroxisome proliferation. Chem. Biol. Interact. 99 (1996) 205-218